Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY231 in Relapsed/Refractory B-Cell Lymphoma/Leukemia
NCT06890065Phase 1Recruiting
- Sponsor
- Genocury Biotech
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JY231 in B cell lymphoma and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Genocury Biotech. Primary endpoints: Incidence of adverse events after infusion at 24 months and Maximal Tolerated Dose at 28 days. Started Mar 2025; status: recruiting.
02
Drugs
JY231
03
Conditions
B cell lymphomaB cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06890065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890065.